Webcast ImageWebcast
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference  (Replay)
03/21/17 at 3:55 p.m. ET
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference
Tuesday, March 21, 2017 3:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
December 20, 2012BioTime Announces the Appointment of Jeffrey Janus as Vice President
Adds senior executive with significant experience in sales and marketing of research products ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 20, 2012-- BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing. Mr. Janus’ primary focus will be to create, market, and sell research products for BioTime and its subsidiaries in the expanding field of regenerative medicine. M... 
Printer Friendly Version
December 18, 2012BioTime Reports Isolation of Seven Diverse Cartilage and Bone Cell Types From Human Embryonic Stem Cells
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 18, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of manufacturing seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells. The paper, scheduled to be published online (ahead of print) at 1600 GMT today i... 
Printer Friendly Version
December 04, 2012BioTime CEO Dr. Michael West Presents Product Development Update at World Stem Cell Summit 2012
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 4, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, Ph.D. will provide an update today on five products being developed by BioTime and its subsidiaries during a presentation at the World Stem Cell Summit 2012 in West Palm Beach, Florida in the session on “Developing Combi... 
Printer Friendly Version
November 29, 2012BioTime CEO Dr. Michael West to Present at World Stem Cell Summit 2012
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 29, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the World Stem Cell Summit 2012 in West Palm Beach, Florida on Tuesday, December 4, 2012. Dr. West will be presenting in the session on “Developing Combination Products: Cells, Genes, and Dev... 
Printer Friendly Version
November 26, 2012BioTime Announces Passing of Director Abraham E. Cohen
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 26, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced with sadness that Abraham (Barry) E. Cohen, a member of its Board of Directors, passed away on Thursday, November 22, 2012 at the age of 76. Mr. Cohen has been a valued member of the Board of Directors and was a member of several committees, including the Audit Committee. Mr. Cohen had a long career in the pharmaceutical industry, where he played a key ... 
Printer Friendly Version
November 15, 2012BioTime and BioTime Acquisition Corporation Announce Combined $10 Million Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 15, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent for a $10 million investment from a private investor to provide financing for the recently announced proposed acquisition of Geron Corp.’s stem cell assets by BAC. Under the terms outlined in the letter of inte... 
Printer Friendly Version
November 15, 2012BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 15, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation. The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Geron’s discontinued human embryon... 
Printer Friendly Version
November 14, 2012BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents™ Portal
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 14, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents™ (http://bioreagents.lifemapsc.com/), a new portal offering researchers access to BioTime’s research product lines including PureStem™ human progenitor cell lines, PureStem™ packages, clinical and research grade human embryonic stem cell lines (hES), HyStem® hydrogels, culture media, and ... 
Printer Friendly Version
November 09, 2012BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 9, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 and highlighted recent corporate accomplishments. Financial Results Net Loss Net loss attributable to BioTime for the third quarter of 2012 w... 
Printer Friendly Version
November 07, 2012BioTime and Subsidiary Cell Cure Neurosciences Ltd. Announce Financing
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that they have entered into a share purchase agreement through which BioTime agreed to purchase 87,456 Cell Cure ordinary shares in exchange for 906,735 BioTime common shares. As a result of the share purchase, BioTime will own, directly and through its wholly owned subsidiary ES Ce... 
Printer Friendly Version
October 18, 2012BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 18, 2012-- BioTime, Inc. (NYSE MKT: BTX) today issued the following letter to the shareholders of Geron Corporation (Nasdaq: GERN) regarding Geron’s stem cell assets: October 18, 2012 AN OPEN LETTER TO GERON SHAREHOLDERS Dear Geron Shareholders: As you know, during November 2011, Geron Corporation (Nasdaq: GERN) announced that it was discontinuing its stem cell resea... 
Printer Friendly Version
September 28, 2012BioTime Forms BioTime Acquisition Corporation
Subsidiary will seek to acquire assets and businesses in the stem cell and regenerative medicine fields Dr. Thomas Okarma appointed Chief Executive Officer of the new company ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 28, 2012-- BioTime, Inc. (NYSE MKT: BTX), an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, anno... 
Printer Friendly Version
September 19, 2012BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2012
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 19, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Stem Cells USA & Regenerative Medicine Congress 2012 in Cambridge, MA on Thursday, September 20, 2012. Dr. West will speak on “Second Generation hES Cell-Based Therapies: Achieving Purity and Scalability in the Midst of Diversity” in the session Developments in Novel Therapeutics.... 
Printer Friendly Version
August 27, 2012BioTime Obtains Expanded License to HyStem® Technology
- BioTime now holds exclusive worldwide license for all human medical applications of the core HyStem® technology - ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 27, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem® technology. Under the ... 
Printer Friendly Version
August 16, 2012BioTime and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers
Collagen Type X determined to be a protein specifically associated with tumor vasculature Antibodies to detect the protein planned to be one component of PanC-DxTM, a blood-based screen for multiple types of solid tumors ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 16, 2012-- BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced the publication of a scientific rep... 
Printer Friendly Version
August 09, 2012BioTime Announces Second Quarter 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2012 and highlighted recent corporate accomplishments. Financial Results Net Loss Net loss attributable to BioTime, Inc. for the second quarter of 2012 was $5.5 millio... 
Printer Friendly Version
July 17, 2012BioTime Signs Agreements with Jade Therapeutics for Ophthalmological Drug Delivery Applications of HyStem® Technology
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 17, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform. Under the agreements, BioTime will provide Jade with clinical-grade H... 
Printer Friendly Version
July 16, 2012BioTime CEO Dr. Michael West to Present at the 2012 Agora Financial Investment Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 16, 2012-- BioTime, Inc. (NYSE MKT:BTX) announced today that Chief Executive Officer Michael D. West, Ph.D. will present at the 2012 Agora Financial Investment Symposium on Tuesday, July 24, 2012, 4:40 p.m. PDT, at the Fairmont Hotel in Vancouver, British Columbia, Canada. Dr. West will speak on “The Stem Cell Revolution: Designing First-in-Class Therapies for Age-Related Degenerative Disease,” including an upda... 
Printer Friendly Version
May 30, 2012BioTime CEO Dr. Michael West to Present at the Jefferies 2012 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 30, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that its Chief Executive Officer, Michael D. West, Ph.D., will provide a corporate update at the Jefferies 2012 Global Healthcare Conference in New York City on Monday, June 4, 2012 at 3:30 p.m. ET. The presentation will be webcast and may be accessed at http://wsw.com/webcast/jeff68/btx/ or under “Investor Presentations” on BioTime's website at www.biot... 
Printer Friendly Version
May 23, 2012BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08
ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 23, 2012-- XenneX, a Division of LifeMap Sciences, Inc. and BioTime, Inc. (NYSE Amex:BTX), announced today the release of GeneCards®, Version 3.08, on May 20, 2012. The new release is available at www.genecards.org. The new GeneCards® release includes more than 94,500 gene entries. One of the important enhancements is the display of about 52,000 non-protein-coding RNA genes, more t... 
Printer Friendly Version
May 22, 2012BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 22, 2012-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary LifeMap Sciences, Inc. has entered into a license agreement with Yeda Research and Development Company Ltd, the technology transfer arm of the Weizmann Institute of Science, to market a new database called MalaCards. A database of human diseases that is based on the GeneCards® platform, MalaCards contains computerized “cards” classifyin... 
Printer Friendly Version
May 21, 2012BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc.
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 21, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc. today announced that they have completed the acquisition of XenneX, Inc. through a merger of XenneX into LifeMap Sciences. The definitive merger agreement was previously announced on April 20, 2012. LifeMap Sciences now holds the exclusive, worldwide licenses to market GeneCards® and PanDaTox from Yeda Research and Develop... 
Printer Friendly Version
May 14, 2012HyStem(R)-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease
ALAMEDA, Calif., May 14, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE MKT: BTX) announced today the publication of a scientific paper demonstrating the effectiveness of HyStem(R)-C in the transplantation of heart muscle-derived cells in an animal model of heart disease. The paper, "Functional performance of human cardiosphere-derived cells delivered in an in situ polymerizable hyaluronan-gelatin hydrogel," is published online (ahead of print) in the ... 
Printer Friendly Version
May 10, 2012BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments
Alameda, Calif., May 10, 2012 - BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2012 and highlighted recent corporate accomplishments. Financial Results Net Loss Net loss attributable to BioTime, Inc. for the first quarter of 2012 was $5.0 million or $0.10 per share, compared to a net loss of $3.4 million or $0.07 per share for the same peri... 
Printer Friendly Version
April 23, 2012BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO Michael West, Ph.D. will provide an update on the development of OTX-CP07 by BioTime's subsidiary OrthoCyte Corporation at an investor meeting in New York City. OTX-CP07 is a combination product with human embryonic cartilage progenitors manufactured from human embryonic stem cells formulated with BioTime's proprietary cell delivery device ReneviaTM. Dr. West will describe stu... 
Printer Friendly Version
April 23, 2012BioTime Provides Update on ReneviaTM Product Development
- Product development on track for CE Marking by 2013 - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of ReneviaTM (formerly known as HyStem(R)-Rx) at an investor meeting in New York City. In his presentation, Dr. Tew will discuss the global distribution network marketing the HyStem(R) line of rese... 
Printer Friendly Version
April 23, 2012BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells
- First demonstration of a scalable source of highly purified and identified progenitor cells capable of making definitive (non-hypertrophic) cartilage - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the treatment of osteoar... 
Printer Friendly Version
April 20, 2012BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
Acquisition will integrate GeneCards(R) and associated databases in a centralized resource called "LifeMap" LifeMap Sciences will use new family of online databases to promote the sale of stem cell research products and for discovery of regenerative medicine therapeutic products, based on BioTime's ACTCellerate(TM) human progenitor cell lines ALAMEDA, Calif. & CAMBRIDGE, Mass., Apr... 
Printer Friendly Version
April 18, 2012BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference
ALAMEDA, Calif., Apr 18, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Future Leaders in the Biotech Industry conference on Friday, April 20, 2012, 9:00 a.m. EDT, at the Millennium Broadway Hotel in New York City. Dr. West will present a corporate overview of BioTim... 
Printer Friendly Version
April 16, 2012BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012
ALAMEDA, Calif., Apr 16, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 8th GTC Stem Cell Summit 2012 in Boston, Massachusetts at 3:45 p.m. EDT on Thursday, April 19, 2012. Dr. West will speak on recent trends in the stem cell industry and will provide an up... 
Printer Friendly Version
April 12, 2012BioTime Board of Directors Forms Science and Technology Committee
- Advancing product development efforts - ALAMEDA, Calif., Apr 12, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX) today announced that its Board of Directors has recently formed a Science and Technology Committee to oversee the development and commercialization of BioTime's technology and products in regenerative medicine and oncology. The three-member committee will work with officers and employees of BioTime and its subsidiaries to overs... 
Printer Friendly Version
March 21, 2012BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 21, 2012-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer, Michael D. West, Ph.D., will present a corporate overview of BioTime and its subsidiaries with an update on recent developments at the 2012 Maxim Group Growth Conference on Monday, March 26, 2012, 11:00 a.m. EDT, at the Gr... 
Printer Friendly Version
March 14, 2012 BioTime Announces Fourth Quarter and Fiscal Year End 2011 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 14, 2012--  BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the fourth quarter and year ended December 31, 2011 and highlighted recent corporate accomplishments. "At the forefront of our corporate strategy is a plan to develop and acquire novel technologies in the stem cell field and to establish one of the broadest sets of capabilit... 
Printer Friendly Version
March 08, 2012BioTime to Present at ROTH 24th Annual Growth Stock Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 8, 2012-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Financial Officer, Peter S. Garcia, will present a corporate overview of BioTime and its subsidiaries at the ROTH 24th Annual Growth Stock Conference. The presentation will take place on Tuesday, March 13, 2012, at 9:30 a.m. PDT at The Ritz-Carlton ... 
Printer Friendly Version
February 17, 2012BioTime CEO Michael D. West to Present at New York Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 17, 2012-- BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 7th Annual New York Stem Cell Summit at Bridgewaters New York City on Tuesday, February 21, 2012 at 8:48 a.m. ET. Dr. West will provide an update and new information on the Compan... 
Printer Friendly Version
January 24, 2012BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 24, 2012-- BioTime, Inc. (NYSE Amex:BTX) today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100. Wistar Institute researchers have demonstrated pivotal roles for this gene in both cancer and stem cell biology. Scientists at BioTime’s subsidiaries OncoCyte Corporation and ReCyte Therapeutics plan to apply ... 
Printer Friendly Version
January 03, 2012BioTime to Produce Stem Cells for Research in Muscle Disorders
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 3, 2012-- BioTime, Inc. (NYSE Amex: BTX) today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois. The muscle cell lines will display the genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal... 
Printer Friendly Version